DZ3216A1 - Inhibiteurs tricycliques de poly(adp-ribose) polymerases - Google Patents

Inhibiteurs tricycliques de poly(adp-ribose) polymerases

Info

Publication number
DZ3216A1
DZ3216A1 DZ003216A DZ003216A DZ3216A1 DZ 3216 A1 DZ3216 A1 DZ 3216A1 DZ 003216 A DZ003216 A DZ 003216A DZ 003216 A DZ003216 A DZ 003216A DZ 3216 A1 DZ3216 A1 DZ 3216A1
Authority
DZ
Algeria
Prior art keywords
ribosis
polymerases
adp
tricyclic
inhibitors
Prior art date
Application number
DZ003216A
Other languages
English (en)
French (fr)
Inventor
Stephen Evan Webber
Donald James Skalitzky
Jayashree Girish Tikhe
Original Assignee
Agouron Pharma
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma, Cancer Rec Tech Ltd filed Critical Agouron Pharma
Application granted granted Critical
Publication of DZ3216A1 publication Critical patent/DZ3216A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DZ003216A 1999-08-31 2000-08-31 Inhibiteurs tricycliques de poly(adp-ribose) polymerases DZ3216A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15214299P 1999-08-31 1999-08-31
PCT/US2000/023882 WO2001016136A2 (en) 1999-08-31 2000-08-31 Tricyclic inhibitors of poly(adp-ribose) polymerases

Publications (1)

Publication Number Publication Date
DZ3216A1 true DZ3216A1 (fr) 2001-03-08

Family

ID=22541675

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ003216A DZ3216A1 (fr) 1999-08-31 2000-08-31 Inhibiteurs tricycliques de poly(adp-ribose) polymerases

Country Status (48)

Country Link
US (1) US6548494B1 (enExample)
EP (1) EP1208104B1 (enExample)
JP (1) JP4272375B2 (enExample)
KR (1) KR20020038742A (enExample)
CN (1) CN1384835A (enExample)
AP (1) AP1553A (enExample)
AR (1) AR035162A1 (enExample)
AT (1) ATE287406T1 (enExample)
AU (1) AU781826B2 (enExample)
BG (1) BG106562A (enExample)
BR (1) BR0015051A (enExample)
CA (1) CA2382404C (enExample)
CO (1) CO5200769A1 (enExample)
CR (1) CR6577A (enExample)
CZ (1) CZ2002613A3 (enExample)
DE (1) DE60017575T2 (enExample)
DK (1) DK1208104T3 (enExample)
DO (1) DOP2000000069A (enExample)
DZ (1) DZ3216A1 (enExample)
EA (1) EA200200306A1 (enExample)
EC (1) ECSP003637A (enExample)
EE (1) EE200200100A (enExample)
ES (1) ES2234657T3 (enExample)
GE (1) GEP20043268B (enExample)
GT (1) GT200000145A (enExample)
HK (1) HK1045509B (enExample)
HR (1) HRP20020271A2 (enExample)
HU (1) HUP0202703A3 (enExample)
IL (1) IL147863A0 (enExample)
IS (1) IS6289A (enExample)
MA (1) MA25876A1 (enExample)
MX (1) MXPA02002138A (enExample)
MY (1) MY135910A (enExample)
NO (1) NO322475B1 (enExample)
NZ (1) NZ516793A (enExample)
OA (1) OA12016A (enExample)
PA (1) PA8501801A1 (enExample)
PE (1) PE20010538A1 (enExample)
PL (1) PL354242A1 (enExample)
PT (1) PT1208104E (enExample)
SI (1) SI1208104T1 (enExample)
SK (1) SK2592002A3 (enExample)
SV (1) SV2003000162A (enExample)
UA (1) UA73144C2 (enExample)
UY (1) UY26323A1 (enExample)
WO (1) WO2001016136A2 (enExample)
YU (1) YU15102A (enExample)
ZA (1) ZA200200830B (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
IL143349A0 (en) * 1999-09-28 2002-04-21 Basf Ag Azepinoindole derivatives, the production and use thereof
DE19946289A1 (de) * 1999-09-28 2001-03-29 Basf Ag Benzodiazepin-Derivate, deren Herstellung und Anwendung
DE10021468A1 (de) * 2000-05-04 2001-11-08 Basf Ag Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
FR2816942B1 (fr) * 2000-11-23 2003-05-09 Sanofi Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
AU2002358650A1 (en) * 2001-12-14 2003-06-30 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
US7026311B2 (en) 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
WO2003103666A2 (en) * 2002-06-07 2003-12-18 Altana Pharma Ag Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones
KR100697746B1 (ko) 2003-01-09 2007-03-22 화이자 인코포레이티드 키나제 저해제로서의 디아제피노인돌 유도체
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
DK1660095T3 (da) * 2003-07-25 2010-05-25 Cancer Rec Tech Ltd Tricykliske PARP-inhibitorer
WO2005035534A1 (ja) * 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
PT2305221E (pt) 2003-12-01 2015-09-03 Cancer Res Inst Inibidores de reparação de danos no adn para tratamento de cancro
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
RU2344138C2 (ru) * 2004-09-22 2009-01-20 Пфайзер Инк. Способ получения ингибиторов поли(адф-рибоза)полимераз
WO2006078711A2 (en) * 2005-01-19 2006-07-27 Mgi Gp, Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp
EP1902057B1 (en) 2005-06-14 2013-10-23 Merck Sharp & Dohme Corp. Macrocyclic heterocyclic aspartyl protease inhibitors
US20090226412A1 (en) 2005-06-24 2009-09-10 Ono Pharmaceutical Co., Ltd., Agent for reduction of bleeding in cerebrovascular disorder
KR20130028149A (ko) * 2005-07-18 2013-03-18 바이파 사이언스 인코포레이티드 암의 치료
WO2007018998A2 (en) * 2005-08-05 2007-02-15 Astrazeneca Ab Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20070292883A1 (en) * 2006-06-12 2007-12-20 Ossovskaya Valeria S Method of treating diseases with PARP inhibitors
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
AU2007292387A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
JP2010502731A (ja) * 2006-09-05 2010-01-28 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤による脂肪酸合成の阻害、及びその治療方法
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
RU2471781C2 (ru) 2007-06-05 2013-01-10 НСАБ, Филиаль аф НьюроСёрч Свиден АБ, Сверийе Новые двузамещенные фенилпирролидины в качестве модуляторов кортикальной катехоламинергической нейротрансмиссии
WO2008154129A1 (en) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
EP2188278A1 (en) 2007-09-14 2010-05-26 AstraZeneca AB Phthalazinone derivatives
US7732491B2 (en) * 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
CA2705417A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
EP2224804A4 (en) * 2007-12-07 2011-06-01 Bipar Sciences Inc TREATMENT OF CANCER WITH COMBINATIONS OF TOPOÎSOMERASE INHIBITORS AND PARP INHIBITORS
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
WO2009100159A2 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
CN102238945B (zh) 2008-10-07 2014-10-29 阿斯利康(英国)有限公司 药物制剂514
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
WO2014037313A1 (de) * 2012-09-05 2014-03-13 Bayer Cropscience Ag Verwendung substituierter benzodiazepinone und benzazepinone oder deren salze als wirkstoffe gegen abiotischen pflanzenstress
EP3424909A1 (en) * 2014-01-05 2019-01-09 Washington University A poly (adp-ribose) polymerase-1 (parp-1) inhibitor and uses therefor
CA2993270C (en) 2015-07-23 2019-07-16 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
MA46779A (fr) 2016-11-02 2019-09-11 Health Research Inc Traitement combiné avec des conjugués anticorps-médicament et des inhibiteurs de parp
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018197461A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
PE20211305A1 (es) 2018-01-05 2021-07-20 Cybrexa 1 Inc Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas
CN111819282A (zh) 2018-03-13 2020-10-23 欧恩科斯欧公司 对抗癌症治疗中获得性耐药性的Dbait分子
CN112351778B (zh) * 2018-06-28 2023-04-04 江苏恒瑞医药股份有限公司 稠合三环杂环类化合物及其治疗用途
JP7584802B2 (ja) * 2018-08-24 2024-11-18 アドライ・ノーティ・バイオファーマ・カンパニー・リミテッド 高活性ｓｔｉｎｇタンパク質アゴニスト
CN113195473B (zh) * 2018-12-14 2022-11-22 江苏恒瑞医药股份有限公司 三环化合物作为sting激动剂及其制备方法和医药用途
BR112021015149A2 (pt) * 2019-02-02 2021-09-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Análogo de indolo heptamil oxima como inibidor de parp
CN111909157B (zh) * 2019-05-07 2023-02-03 南京药石科技股份有限公司 Ezh2抑制剂及其用途
CR20220058A (es) 2019-07-10 2022-07-19 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos
JP7675060B2 (ja) 2019-07-10 2025-05-12 サイブレクサ ３，インコーポレイテッド 治療薬としての微小管標的化剤のペプチドコンジュゲート
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CA3176206A1 (en) 2020-04-28 2021-11-04 Debnath Bhuniya Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
MX2023008146A (es) 2021-01-08 2023-07-24 Cybrexa 2 Inc Proceso para preparar un resto enlazador de conjugados.
WO2022155172A1 (en) 2021-01-13 2022-07-21 Cybrexa 3, Inc. Peptide conjugates of therapeutics
MX2023011793A (es) 2021-04-08 2023-10-12 Rhizen Pharmaceuticals Ag Inhibidores de poli(adenosin difosfato-ribosa) polimerasa.
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer
WO2025106920A1 (en) * 2023-11-15 2025-05-22 Yale University Parp pet imaging agents and methods of using the same

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1052390A (enExample) 1964-03-24
US3642820A (en) * 1969-11-03 1972-02-15 Upjohn Co 4 5-dihydropyrrolo(3 2 1-jk)(1 4)bezodiazepines
US3734919A (en) * 1969-11-03 1973-05-22 Upjohn Co 4,5-di-hydropyrrolo(3,2,1-jk)(1,4)benzodiazepin-7(6h)-ones and 4,5-di-hydropyrrolo(1,2,3-ef)(1,5)benzodiazepin-6(7h)-ones
DE2056215A1 (de) 1970-11-16 1972-05-18 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Verfahren zur Herstellung von N-Mono-(beta-Cyanäthyl>anilinen
US3883590A (en) 1971-06-01 1975-05-13 Universal Oil Prod Co Preparation of n-alkylarylcarboxamides
US3978066A (en) 1973-11-06 1976-08-31 Ayerst, Mckenna And Harrison Ltd. Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives
US3900477A (en) 1973-11-06 1975-08-19 Ayerst Mckenna & Harrison 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives
US3950343A (en) 1973-11-06 1976-04-13 Ayerst, Mckenna And Harrison Ltd. Pyrroloisoquinoline derivatives
JPS57144286A (en) 1981-03-02 1982-09-06 Takeda Chem Ind Ltd Azepinoindole derivative and its preparation
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
DE4125292A1 (de) 1991-07-31 1993-02-04 Kali Chemie Pharma Gmbh 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5342946A (en) 1992-12-02 1994-08-30 Guilford Pharmaceuticals Inc. Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors
CN1114834A (zh) 1993-09-28 1996-01-10 大塚制药株式会社 抗糖尿病剂
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5561161A (en) 1994-03-25 1996-10-01 Oxigene, Inc. Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
ES2105959B1 (es) 1995-01-17 1998-07-01 Zeneca Pharma Sa Derivados de 1,4-dioxido de quinoxalina, procedimiento de preparacion y de utilizacion.
US5756548A (en) 1995-04-03 1998-05-26 Centaur Pharmaceuticals, Inc. Acetamidobenzamide compounds for neurodegenerative disorders
US5659082A (en) 1995-04-03 1997-08-19 Centaur Pharmaceuticals, Inc. Nitro- and aminobenzamide compounds for neurodegenerative disorders
PT841924E (pt) 1995-08-02 2003-02-28 Univ Newcastle Ventures Ltd Compostos de benzimidazolo
HUT76302A (en) 1995-11-30 1997-07-28 Chinoin Gyogyszer Es Vegyeszet Quinoxaline derivatives, pharmaceutical compositions containing them and process for producing them
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
WO1998051307A1 (en) 1997-05-13 1998-11-19 Octamer, Inc. METHODS FOR TREATING INFLAMMATION, INFLAMMATORY DISEASES, ARTHRITIS AND STROKE USING pADPRT INHIBITORS
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
AU9298198A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
AU9298098A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
EP1077944A1 (en) 1998-05-15 2001-02-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, compositions, and methods for inhibiting parp activity
CA2332239A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity

Also Published As

Publication number Publication date
DE60017575D1 (de) 2005-02-24
BG106562A (bg) 2003-03-31
WO2001016136B1 (en) 2001-11-15
HK1045509B (en) 2005-04-29
AR035162A1 (es) 2004-05-05
JP4272375B2 (ja) 2009-06-03
CA2382404C (en) 2009-03-24
ATE287406T1 (de) 2005-02-15
JP2003513015A (ja) 2003-04-08
EP1208104B1 (en) 2005-01-19
AU7338900A (en) 2001-03-26
MA25876A1 (fr) 2003-10-01
NO20020421D0 (no) 2002-01-28
HUP0202703A3 (en) 2004-12-28
UY26323A1 (es) 2001-04-30
HUP0202703A2 (hu) 2002-12-28
PA8501801A1 (es) 2002-08-26
PL354242A1 (en) 2003-12-29
AU781826B2 (en) 2005-06-16
GEP20043268B (en) 2004-06-25
DOP2000000069A (es) 2002-08-30
ES2234657T3 (es) 2005-07-01
DK1208104T3 (da) 2005-05-02
AP1553A (en) 2006-01-18
HRP20020271A2 (en) 2005-12-31
ZA200200830B (en) 2003-03-26
PT1208104E (pt) 2005-04-29
PE20010538A1 (es) 2001-05-22
SK2592002A3 (en) 2002-10-08
UA73144C2 (en) 2005-06-15
IS6289A (is) 2002-02-27
ECSP003637A (es) 2002-03-25
EP1208104A2 (en) 2002-05-29
CZ2002613A3 (cs) 2002-08-14
NZ516793A (en) 2004-03-26
MXPA02002138A (es) 2003-08-20
MY135910A (en) 2008-07-31
NO20020421L (no) 2002-04-25
YU15102A (sh) 2004-12-31
CR6577A (es) 2003-12-05
CO5200769A1 (es) 2002-09-27
DE60017575T2 (de) 2005-06-09
CN1384835A (zh) 2002-12-11
SI1208104T1 (en) 2005-06-30
EA200200306A1 (ru) 2002-08-29
BR0015051A (pt) 2002-06-25
IL147863A0 (en) 2002-08-14
HK1045509A1 (en) 2002-11-29
CA2382404A1 (en) 2001-03-08
NO322475B1 (no) 2006-10-09
EE200200100A (et) 2003-06-16
US6548494B1 (en) 2003-04-15
WO2001016136A2 (en) 2001-03-08
KR20020038742A (ko) 2002-05-23
WO2001016136A3 (en) 2001-06-21
GT200000145A (es) 2002-02-21
OA12016A (en) 2006-04-19
SV2003000162A (es) 2003-07-29

Similar Documents

Publication Publication Date Title
DZ3216A1 (fr) Inhibiteurs tricycliques de poly(adp-ribose) polymerases
EE200100364A (et) Polü(ADP-riboos)polümeraaside tritsüklilised inhibiitorid
DK1224174T3 (da) Benzodiazepinderivater
NO20021691D0 (no) Benzodiazepinderivater
NO20016334D0 (no) Boresystem
ID30132A (id) Turunan-turunan pirazol trisiklik
PT1224195E (pt) C-aril-glicosidos inibidores de tgls2
DE69901517D1 (de) Zapfhahn
DE60011523D1 (de) Türschloss
DE60044611D1 (de) Alicyclisches kohlenwasserstoffcopolymer
EP1209190A4 (en) Nucleating agent
DE50011953D1 (de) Bohrwerkzeug
DE50011611D1 (de) Bohrwerkzeug
BR0013140B1 (pt) conjunto de maÇaneta.
DE69918938D1 (de) Schlüsseleinführungsvorrichtung
DE60028701D1 (de) Synchronisiereinrichtung
DE50011494D1 (de) Bohrwerkzeug
DE50011100D1 (de) Bohrwerkzeug
MA26795A1 (fr) Analgesiques tricycliques.
DE10085310T1 (de) Schloß
ATE259816T1 (de) Tricyclische benzoylcyclohexandion-derivate
FI990185A0 (fi) Rotaattori
DE60035019D1 (de) Synchronisiereinrichtung
SE9901473D0 (sv) Nucleosides
DK1090019T3 (da) Adenosinderivater